Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772410 | 0.94 | GSK3A (0.34) | GSK3ABDKRB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6583729 | 0.80 | — | — | |
| SCHEMBL5776910 | 0.77 | GSK3A (0.35) | GSK3ABDKRB1ALDH1A1MEN1KMT2A | |
| SCHEMBL5774080 | 0.77 | GRM2 (0.30) | — | |
| SCHEMBL6288862 | 0.76 | ALPL (0.32) | — | |
| SCHEMBL5776518 | 0.76 | OPRM1 (0.31) | CYP3A4ALDH1A1MEN1KMT2A | |
| SCHEMBL6291852 | 0.73 | CNR2 (0.35) | CYP3A4ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5778216 | 0.73 | ICMT (0.35) | ALDH1A1SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL6579675 | 0.73 | TYMS (0.32) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5773302 | 0.72 | MAPK1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406888-B1 | SUBSTITUTED Y-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2006-05-24 | — | — | EP | claimed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | claimed |
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406888-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004483-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| EP-1406888-B1 | SUBSTITUTED Y-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2006-05-24 | — | — | EP | disclosed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | disclosed |
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406888-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004483-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRIN1, GRIN3A, GRIK5 | GSK3A 1037/4885CYP3A4 3621/4885HSD11B1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.